KALA BIO Investor Relations Material
Latest events
Q2 2022
KALA BIO
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from KALA BIO Inc
Access all reports
KALA BIO Inc (formerly Kala Pharmaceuticals, Inc.) focuses on the discovery, development, and commercialization of therapies using its proprietary mucus penetrating particles technology for the treatment of eye diseases. The company offers KPI-121 CL or KP201 CL, an ophthalmic solution that contains a contact lens to deliver drugs through the human eye's mucus layer directly into the anterior chamber of the eye. It also provides KPI-121 CL or KP201 CL in an ampul form.
Latest articles
Sergey Brin's Role in Shaping the Tech World
Explore Sergei Brin's journey from a Moscow immigrant to co-founding Google, detailing key developments and Alphabet's creation.
29 Apr 2024
Four Decades of IPOs: An Overview
An overview of the stock and IPO market from the 80's until today, highlighting important events and trends.
24 Apr 2024
Larry Page: The Mastermind Behind Google
Explore the journey of Larry Page from a tech-savvy youth to co-founding Google and leading Alphabet.
24 Apr 2024
Ticker symbol
Country
🇺🇸 United States